Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2458)	7/22/2005 5:31:32 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 3044

No clue. Got sick of MLNM long ago and don't really see all that much new. The BT juniors would have to go up another 75% before MLNM would compete for investment attention from me. Gazzillions of shares, debt, blech. Further, there are Rules 2 and 3 for taking an initial position: Stay away from BTs with drug sales. Stay away from BTs >$400m MC, this number can move up and down. (BTW, FLT3 is totally hot but Sheryl Crow is not.)

To: scaram(o)uche who wrote (2458)	7/22/2005 5:46:19 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

>>how is the FLT3 inhibitor?>> I don't think MLN518 is one of their priority programs. There were no slides for that product candidate at the R&D day. The potential "market" seems to be limited and there are a couple of other companies being ahead of them developing products aimed at the same pathway. Erik